Abbisko Cayman Ltd
02256
Company Profile
Business description
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has only one business segment which is the development of medicines.
Contact
Building 3, No. 898 Halei Road
Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai
CHNT: +86 2168912098
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
278
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,342.40 | 14.40 | -0.15% |
| CAC 40 | 8,225.63 | 0.15 | -0.00% |
| DAX 40 | 24,239.89 | 32.10 | 0.13% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,645.62 | 67.05 | 0.70% |
| HKSE | 26,427.16 | 267.01 | 1.02% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 50,292.08 | 992.43 | 2.01% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 53.25 | 0.79% |
| S&P/ASX 200 | 9,045.20 | 12.60 | -0.14% |
| SSE Composite Index | 3,991.35 | 41.04 | 1.04% |